Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
22 November 2024

Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study

Authors: Yestle Kim https://orcid.org/0009-0007-0263-9384 [email protected], Joseph Medicis, Matthew Davis https://orcid.org/0000-0003-0443-0465, Dominic Nunag, and Robert Gish https://orcid.org/0000-0001-6306-3189Author Info & Affiliations
Volume 13, Number 12
https://doi.org/10.57264/cer-2024-0096
PDFFormats

Abstract

Aim: Non-alcoholic steatohepatitis (NASH), or metabolic dysfunction-associated steatohepatitis (MASH), is a severe form of non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated liver disease (MASLD), that may progress to advanced liver disease. Costs associated with progression are not well characterized. This study sought to quantify costs and healthcare resource utilization (HRU) associated with NASH progression. Methods: Patients were included if diagnosed with NASH (ICD-10: K75.81) in 100% Medicare claims data (2015–2021) who were ≥66 years at index (diagnosis), continuously enrolled in Parts A, B and D for ≥12 months prior to and 6 months following index (unless death) and who had no evidence of other causes of liver disease. Patient-time was categorized into five severity states: non-cirrhotic NASH, compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC) and liver transplant (LT). Annualized HRU and costs were calculated during the study periods overall and stratified by occurrence and timing of progression. Results: In 14,806 unique patients (n = 12,990 non-cirrhotic NASH; 1899 CC; 997 DCC; 209 HCC; 140 LT), mean age and follow-up were 72.2 and 2.8 years, respectively. Average annualized costs increased from baseline following diagnosis, generally scaling with severity: $16,231 to $27,044; $25,122 to $57,705; $40,613 to $181,036; $36,549 to $165,121 and $35,626 to $108,918 in NASH; CC; DCC; HCC; and LT; respectively. Non-cirrhotic NASH and CC patients with progression had higher follow-up spending (1.6x for NASH; 1.7x for CC) than non-progressors (both p < 0.001), 2.8 and 6.1-times higher odds of an inpatient stay and 2.6 and 3.6-times higher odds to be in the top 20% of spenders, respectively, relative to non-progressors (both p < 0.001). Patients progressing within a year had costs 1.4, 1.6, 1.7 and 2.2-times more than year 2, 3, 4 and 5 progressors' costs, respectively, for non-cirrhotic NASH and 1.3, 1.8, 2.0 and 2.2-times more than year 2, 3, 4 and 5 progressors' costs, respectively, for CC. Conclusion: NASH progression is associated with high costs that increase in more severe disease states. Slower progression is associated with lower costs, suggesting a potential benefit of therapies that may delay or prevent progression.

Supplementary Material

File (supplementary materials.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Pouwels S, Sakran N, Graham Y et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22(1), 63 (2022).
PubMed
Google Scholar
2.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73–84 (2016).
PubMed
Google Scholar
3.
Younossi Z, Stepanova M, Ong J et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 19(3), 580–589.e5 (2021).
PubMed
Google Scholar
4.
Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 34(7), 969–977.e2 (2022).
PubMed
Google Scholar
5.
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1), 328–357 (2018).
PubMed
Google Scholar
6.
Loomba R, Adams LA. The 20% Rule of NASH Progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70(6), 1885–1888 (2019).
PubMed
Google Scholar
7.
Loomba R, Wong R, Fraysse J et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment. Pharmacol. Ther. 51(11), 1149–1159 (2020).
PubMed
Google Scholar
• Provided novel real-world evidence on progression rates of non-alcoholic fatty liver disease (NAFLD) among a 20% Medicare representative sample of adult patients.
8.
Sanyal AJ, Harrison SA, Ratziu V et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70(6), 1913–1927 (2019).
PubMed
Google Scholar
9.
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA 323(12), 1175–1183 (2020).
PubMed
Google Scholar
10.
Alqahtani SA, Schattenberg JM. NAFLD in the elderly. Clin. Interv. Aging. 16, 1633–1649 (2021).
PubMed
Google Scholar
11.
Chen TP, Lai M, Lin WY, Huang KC, Yang KC. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: a community-based study. J Gastroenterol Hepatology. 35(9), 1636–1643 (2020).
PubMed
Google Scholar
12.
Miyaaki H, Ichikawa T, Nakao K et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 28(4), 519–524 (2008).
PubMed
Google Scholar
13.
Pais R, Charlotte F, Fedchuk L et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 59(3), 550–556 (2013).
PubMed
Google Scholar
14.
Younossi Z, Aggarwal P, Shrestha I et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 4(9), 100525 (2022).
PubMed
Google Scholar
• This systematic review provided evidence of the substantial health-related quality of life burden associated with non-alcoholic steatohepatitis (NASH) that increases with disease progression.
15.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes. Facts. 9(2), 65–90 (2016).
PubMed
Google Scholar
16.
Cusi K, Isaacs S, Barb D et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Prac. 28(5), 528–562 (2022).
PubMed
Google Scholar
17.
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J. Gastroenterol. 24(30), 3361–3373 (2018).
PubMed
Google Scholar
18.
Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 18(6), 373–392 (2021).
PubMed
Google Scholar
19.
US Food & Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. (2024) (Accessed: 28 March 2024). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease#:∼:text=Today%2C%20the%20U.S.%20Food%20and,along%20with%20diet%20and%20exercise
Google Scholar
20.
Harrison SA, Bedossa P, Guy CD et al. A Phase III, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390(6), 497–509 (2024).
PubMed
Google Scholar
•• This trial provided evidence on the efficacy and safety of resmetrion for treatment of patients with biopsy-confirmed NASH and fiborsis stage F1B, F2 or F3.
21.
Madrigal Pharmaceuticals. Madrigal Pharmaceuticals announces new data from the Phase III MAESTRO-NASH study of Rezdiffra™ (resmetirom) presented at the EASL Congress. (2024) (Accessed: 19 July 2024). https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-new-data-phase-3-maestro-nash
Google Scholar
22.
Sinakos E, Liava C, Loomba R. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. Ann. Gastroenterol. 35(3), 213–225 (2022).
PubMed
Google Scholar
23.
Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology 68(6), 2230–2238 (2018).
PubMed
Google Scholar
• This real-world claims study demonstrated the substantial economic burden (total healthcare costs and resource utilization) assocaited with NAFLD in the United States.
24.
Gordon SC, Kachru N, Parker E, Korrer S, Ozbay AB, Wong RJ. Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the fibrosis-4 score. Hepatol. Commun. 4(7), 998–1011 (2020).
PubMed
Google Scholar
• Provided evidence that patients with NAFLD/NASH with advanced fibrosis incur significant healthcare costs and healthcare resource utilization. Additionally, healthcare costs and healthcare resource utilization increased with liver fibrosis severity.
25.
Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A. Early cost-effectiveness and price threshold analyses of resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis. Pharmacoecon. Open. 7(1), 93–110 (2023).
PubMed
Google Scholar
26.
Gordon SC, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients. Am. J. Gastroenterol. 115(4), 562–574 (2020).
PubMed
Google Scholar
27.
Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The economic burden of non-alcoholic steatohepatitis: a systematic review. Pharmacoeconomics 40(8), 751–776 (2022).
PubMed
Google Scholar
28.
Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. J. Clin. Gastroenterol. 55(10), 891–902 (2021).
PubMed
Google Scholar
• This study of patients with NASH demonstrated that healthcare costs and healthcare resource utilization increase in more severe disease states.
29.
Langan SM, Schmidt SA, Wing K et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 363, k3532 (2018).
PubMed
Google Scholar
30.
Husereau D, Drummond M, Augustovski F et al. CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. (2022) (Accessed: 2 May 2024). https://www.equator-network.org/reporting-guidelines/cheers/
Google Scholar
31.
Hagström H, Adams LA, Allen AM et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology 74(1), 474–482 (2021).
PubMed
Google Scholar
32.
Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6), 1966–1986 (2023).
PubMed
Google Scholar
33.
Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re V 3rd. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol. Drug Saf. 21(7), 765–969 (2012).
PubMed
Google Scholar
34.
Chronic Conditions Warehouse Virtual Research Data Center. Data Output Review Process Version 2.3 (2023) (Accessed: 2 May 2024). https://www2.ccwdata.org/
Google Scholar
35.
Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv. Res. 53(1), 175–196 (2018).
PubMed
Google Scholar
36.
Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part III. Value Health. 12(8), 1062–1073 (2009).
PubMed
Google Scholar
37.
Rayabandla S. A review of the characteristics of super-utilizers and evidence based approaches to reduce healthcare utilization. Capstone Experience., 154. (2020) (Accessed: 31 May 2024). https://digitalcommons.unmc.edu/coph_slce/154
Google Scholar
38.
Fishman JC, Qian C, Kim Y et al. Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study. J. Manag. Care Spec. Pharm. 30(9), 929–941 (2024).
PubMed
Google Scholar
• Provides recent evidence on the economic burden of NASH. It demonstrated that healthcare costs and healthcare resource utilization are higher among patients with NASH with cirrhosis and disease progression than without.
39.
Canbay A, Kachru N, Haas JS, Meise D, Ozbay AB, Sowa JP. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann. Transl. Med. 9(8), 615 (2021).
PubMed
Google Scholar
40.
Romero-Gomez M, Kachru N, Zamorano MA, Darba J, Shreay S. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine 99(50), e23506 (2020).
PubMed
Google Scholar
41.
Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: analysis of a French national hospital database. EClinicalMedicine. 25, 100445 (2020).
PubMed
Google Scholar
42.
Petta S, Ting J, Saragoni S et al. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutr. Metab. Cardiovasc. Dis. 30(6), 1014–1022 (2020).
PubMed
Google Scholar
43.
Porayko MK, Articolo A, Cerenzia W, Coleman B, Patel D, Stacy S. Differences in NAFLD/NASH management by provider specialty: opportunities for optimizing multidisciplinary care. J Multidiscip Healthc. 15, 1533–1545 (2020).
Google Scholar
44.
Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 22(1), 335 (2022).
PubMed
Google Scholar
|